Fidson Healthcare PLC


Fidson Healthcare PLC

  • Price (NGN)1.05
  • Today's Change0.09 / 9.38%
  • Shares traded217.20k
  • 1 Year change-52.27%
  • Beta0.6381
Data delayed at least 60 minutes, as of Apr 25 2017 13:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

Fidson Healthcare Plc is a Nigeria-based pharmaceutical manufacturing company. The principal activities of the Company are the manufacture and distribution of pharmaceutical products. The Company's segments include over the counter, ethical product and consumer. The over the counter segment represents the products that may be sold directly to the consumer without a prescription. The ethical products segment represents the drugs, which would be sold to the consumer only on the possession of a valid prescription. The consumer segment represents household items. The Company offers various drug products and formulations across different therapeutic classes and pharmacological segments, which include antacid and ulcer care; anti-diabetic; anti-malaria; cardio-vascular; cough, cold, catarrh and allergies; multivitamin-hematinics; nuero-psychiatry/anti-physiotic; anti-diarrhea; osteo-care; pain-relievers, and thrombo-prophalyti.

  • Revenue in NGN (TTM)7.66bn
  • Net income in NGN316.76m
  • Incorporated--
  • Employees284.00
  • Location
    Fidson Healthcare PLC268, Ikorodu Road, ShomoluP.O.Box 7210LAGOS NigeriaNGA
  • Phone+234 3429102
  • Fax+234 3429106
  • Websitehttp://www.fidson.com/
More ▼

Institutional shareholders

0.23%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management U.K. Ltd.as of 30 Sep 20163.39m0.23%
Data from 30 Sep 2016 - 30 Sep 2016Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.